INmune Bio Inc.
INMB
$1.21
-$0.01-0.82%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 44.48% | 42.89% | 46.48% | -150.95% | 11.66% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -32.27% | 88.73% | 37.17% | 668.00% | 16.69% |
| Change in Net Operating Assets | -34.92% | 70.43% | -140.11% | -87.74% | -51.67% |
| Cash from Operations | 50.13% | 73.27% | 22.14% | 6.48% | 8.72% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -100.00% | 43.71% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | 103.22% | -100.00% | 71.35% | 310.96% |
| Foreign Exchange rate Adjustments | 128.57% | -91.97% | 97.52% | -247.73% | -126.92% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -114.07% | 76.38% | -327.14% | 177.03% | 83.90% |